Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412979 | 1.00 | SPHK1 (0.42) | SPHK1SPHK2SMN1; SMN2NR1H4KCNH2 | |
| SCHEMBL4412893 | 0.85 | SPHK1 (0.47) | SPHK1SPHK2SMN1; SMN2NR1H4KCNH2 | |
| SCHEMBL4422335 | 0.81 | PTGS2 (0.51) | SPHK1SPHK2SMN1; SMN2KCNH2MCHR1 | |
| SCHEMBL4412654 | 0.77 | GPR119 (0.40) | SPHK1SPHK2NR1H4KCNH2MCHR1 | |
| SCHEMBL4424803 | 0.77 | SPHK1 (0.46) | SPHK1SPHK2SMN1; SMN2MCHR1S1PR1 | |
| SCHEMBL4415854 | 0.76 | SPHK2 (0.55) | SPHK1SPHK2MCHR1S1PR1 | |
| SCHEMBL4415893 | 0.76 | SPHK1 (0.41) | SPHK1SPHK2MCHR1S1PR1 | |
| SCHEMBL4415741 | 0.76 | HDAC4 (0.43) | SPHK1SPHK2KCNH2S1PR1 | |
| SCHEMBL4414279 | 0.75 | HDAC4 (0.46) | SPHK1SPHK2MCHR1S1PR1 | |
| SCHEMBL13598291 | 0.75 | GPR119 (0.55) | SPHK1SPHK2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | SPHK1 686/4885SPHK2 754/4885SMN1; SMN2 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.